Search results
Results from the WOW.Com Content Network
They are a class of sympathomimetic agents, each acting upon the beta adrenoceptors. [2] In general, pure beta-adrenergic agonists have the opposite function of beta blockers : beta-adrenoreceptor agonist ligands mimic the actions of both epinephrine - and norepinephrine - signaling, in the heart and lungs, and in smooth muscle tissue ...
Modified-release dosage is a mechanism that (in contrast to immediate-release dosage) delivers a drug with a delay after its administration (delayed-release dosage) or for a prolonged period of time (extended-release [ER, XR, XL] dosage) or to a specific target in the body (targeted-release dosage).
Insulin lispro, sold under the brand name Humalog among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. [5] It is delivered subcutaneously either by injection or from an insulin pump.
“So you can do things that will briefly lower your heart rate—like deep breathing and meditation—but if you are trying to lower your overall heart rate over a longer period of time, the ...
The long acting insulin is given once (usually glargine, Lantus) or twice (usually detemir, Levemir) daily to provide a base, or basal insulin level. Rapid acting (RA) insulin is given before meals and snacks. A similar profile can be provided using an insulin pump where rapid acting insulin is given as the basal and premeal bolus insulin.
Tachycardia, also called tachyarrhythmia, is a heart rate that exceeds the normal resting rate. [1] In general, a resting heart rate over 100 beats per minute is accepted as tachycardia in adults. [1] Heart rates above the resting rate may be normal (such as with exercise) or abnormal (such as with electrical problems within the heart).
Lofexidine, sold under the brand name Lucemyra among others, [1] is a medication historically used to treat high blood pressure; today, it is more commonly used to help with the physical symptoms of opioid withdrawal. [2]
This is an ultralong-acting insulin analogue developed by Novo Nordisk, which markets it under the brand name Tresiba. It is administered once daily and has a duration of action that lasts up to 40 hours (compared to 18 to 26 hours provided by other marketed long-acting insulins such as insulin glargine and insulin detemir).